Northwestern Mutual Wealth Management Co. Invests $4.35 Million in Cardinal Health, Inc. $CAH

Northwestern Mutual Wealth Management Co. bought a new position in shares of Cardinal Health, Inc. (NYSE:CAH - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 18,301 shares of the company's stock, valued at approximately $4,348,000.

Several other large investors have also recently bought and sold shares of the business. Integrated Wealth Concepts LLC lifted its holdings in Cardinal Health by 6.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,363 shares of the company's stock worth $601,000 after buying an additional 280 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Cardinal Health by 198.3% in the 1st quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company's stock valued at $27,000 after acquiring an additional 14,034 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cardinal Health during the 2nd quarter worth about $1,935,000. Cerity Partners LLC raised its position in shares of Cardinal Health by 17.0% during the 2nd quarter. Cerity Partners LLC now owns 40,426 shares of the company's stock worth $6,792,000 after acquiring an additional 5,880 shares in the last quarter. Finally, Nebula Research & Development LLC lifted its stake in Cardinal Health by 34.4% during the second quarter. Nebula Research & Development LLC now owns 10,334 shares of the company's stock worth $1,736,000 after purchasing an additional 2,646 shares during the last quarter. Hedge funds and other institutional investors own 87.17% of the company's stock.

More Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Analyst Ratings Changes

CAH has been the subject of a number of research analyst reports. Leerink Partners set a $292.00 price target on Cardinal Health in a report on Tuesday, August 11th. Citigroup raised their price objective on shares of Cardinal Health from $265.00 to $280.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Robert W. Baird boosted their price objective on shares of Cardinal Health from $251.00 to $274.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. TD Cowen upped their target price on shares of Cardinal Health from $275.00 to $280.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Finally, Morgan Stanley upped their target price on shares of Cardinal Health from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $266.56.

Cardinal Health Trading Down 0.0%

Shares of CAH stock opened at $229.48 on Monday. The company has a market capitalization of $53.37 billion, a P/E ratio of 31.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.49. The business's 50 day moving average is $232.02 and its two-hundred day moving average is $217.86. Cardinal Health, Inc. has a twelve month low of $145.87 and a twelve month high of $258.30.

Cardinal Health (NYSE:CAH - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.42 by $0.49. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The firm had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. During the same period last year, the company earned $2.08 earnings per share. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, equities analysts predict that Cardinal Health, Inc. will post 12.54 earnings per share for the current fiscal year.

Cardinal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a $0.5158 dividend. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health's dividend payout ratio (DPR) is currently 28.49%.

Insider Buying and Selling

In other Cardinal Health news, CEO Deborah Weitzman sold 7,354 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the sale, the chief executive officer directly owned 77,901 shares in the company, valued at approximately $18,341,790.45. The trade was a 8.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Mary C. Scherer sold 2,302 shares of the business's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $237.39, for a total transaction of $546,471.78. Following the sale, the chief accounting officer directly owned 2,811 shares in the company, valued at approximately $667,303.29. This represents a 45.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 210,271 shares of company stock valued at $49,626,657 in the last quarter. Corporate insiders own 0.12% of the company's stock.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source